Boehringer Ingelheim’s adalimumab biosimilar candidate to Humira, BI 695501, has been accepted for regulatory review by both the FDA and the European Medicines Agency (EMA).
The applications for FDA and EMA approvals are supported by top-line results from the completed Phase III study of BI 695501 that were announced in October 2016, which was conducted in patients with active rheumatoid arthritis (RA), according to Boehringer Ingelheim. [www.boehringer-ingelheim.us/press-release/boehringer-ingelheims-adalimumab-biosimilar-candidate-shows-similar-efficacy-and] The results of the study showed that BI 695501 met the clinical study efficacy end points to establish equivalence with Humira in patients with active RA and also met the secondary end points for the efficacy, safety, and immunogenicity of BI 695501 versus Humira.
The Phase III study was a randomized, double-blind, parallel arm, multiple dose, active comparator study in 645 patients diagnosed with moderate to severe active RA who were treated with methotrexate. Each participant was randomized to either BI 695501 or Humira every 2 weeks for 48 weeks. Efficacy was measured in patients with RA by ascertaining the proportion of patients with RA who met American College of Rheumatology 20 (ACR20) criteria at week 12 and week 24 compared with baseline.
If approved, BI 695501 can offer a high-quality, economically sustainable treatment option to patients with inflammatory diseases, said Martina Flammer, Vice President, Clinical Development and Medical Affairs, Specialty Care, at Boehringer Ingelheim, and would be a critical milestone for the company as it seeks to expand treatment options for patients with biosimilars.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.